Information  X 
Enter a valid email address

Company Name matching 'Novartis International AG'

Date
Time Source
Company
Announcement
29 Jul 2019 6:00 am GNW   Factsheet Novartis International AG (0QLR) Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)
26 Jul 2019 1:06 pm GNW   Factsheet Novartis International AG (0QLR) Novartis receives positive CHMP opinion for Lucentis® treatment in preterm infants with retinopathy of prematurity (ROP), a disease causing visual impairment and blindness
22 Jul 2019 6:15 am GNW   Factsheet Novartis International AG (0QLR) Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis
18 Jul 2019 6:00 am GNW   Factsheet Novartis International AG (0QLR) Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased
16 Jul 2019 6:15 am GNW   Factsheet Novartis International AG (0QLR) FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
11 Jul 2019 9:30 pm GNW   Factsheet Novartis International AG (0QLR) Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention
01 Jul 2019 4:30 pm GNW   Factsheet Novartis International AG (0QLR) Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
14 Jun 2019 7:30 am GNW   Factsheet Novartis International AG (0QLR) Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001)
12 Jun 2019 6:20 am GNW   Factsheet Novartis International AG (0QLR) Cosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show
  6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis Cosentyx® first to show efficacy in all key manifestations of psoriatic arthritis
07 Jun 2019 6:00 am GNW   Factsheet Novartis International AG (0QLR) Novartis announces new leader of Pharmaceuticals Business Unit
06 Jun 2019 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible
04 Jun 2019 6:00 pm GNW   Factsheet Novartis International AG (0QLR) Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®
03 Jun 2019 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
  6:00 am GNW   Factsheet Novartis International AG (0QLR) Xolair® (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
01 Jun 2019 12:30 pm GNW   Factsheet Novartis International AG (0QLR) Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
30 May 2019 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis' phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma
24 May 2019 9:12 pm GNW   Factsheet Novartis International AG (0QLR) FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
  5:42 pm GNW   Factsheet Novartis International AG (0QLR) AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
  5:30 pm GNW   Factsheet Novartis International AG (0QLR) AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
23 May 2019 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis highlights company transformation, catalyst-rich pipeline, and strong progress on strategy at Meet Novartis Management investor event
22 May 2019 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
16 May 2019 2:00 pm GNW   Factsheet Novartis International AG (0QLR) Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders
08 May 2019 11:20 pm GNW   Factsheet Novartis International AG (0QLR) Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
  6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis data at AAN show Mayzent's® positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS
07 May 2019 6:55 pm GNW   Factsheet Novartis International AG (0QLR) New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1
  6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians evaluate and discuss early signs of progression to secondary progressive MS
05 May 2019 4:30 pm GNW   Factsheet Novartis International AG (0QLR) AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients
02 May 2019 9:30 pm GNW   Factsheet Novartis International AG (0QLR) Novartis to highlight extensive long-term safety and efficacy data of Aimovig® across the spectrum of migraine at AAN
30 Apr 2019 9:30 pm GNW   Factsheet Novartis International AG (0QLR) New data at AAN reinforce Novartis commitment to transforming the lives of people of all ages who live with neurological conditions
  6:15 am GNW   Factsheet Novartis International AG (0QLR) Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors
24 Apr 2019 6:00 am GNW   Factsheet Novartis International AG (0QLR) Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded
16 Apr 2019 9:45 pm GNW   Factsheet Novartis International AG (0QLR) AveXis data reinforce effectiveness of Zolgensma® in treating spinal muscular atrophy (SMA) Type 1
15 Apr 2019 9:05 pm GNW   Factsheet Novartis International AG (0QLR) Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
11 Apr 2019 6:15 am GNW   Factsheet Novartis International AG (0QLR) Sandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countries
09 Apr 2019 6:00 am GNW   Factsheet Novartis International AG (0QLR) Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off
04 Apr 2019 9:00 pm GNW   Factsheet Novartis International AG (0QLR) Novartis updates on the migraine collaboration with Amgen
03 Apr 2019 6:15 am GNW   Factsheet Novartis International AG (0QLR) Sandoz resubmits biosimilar pegfilgrastim application to US FDA
02 Apr 2019 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis first-in-class Cosentyx® approved in China for psoriasis patients
01 Apr 2019 9:05 pm GNW   Factsheet Novartis International AG (0QLR) AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
  6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre
26 Mar 2019 11:33 pm GNW   Factsheet Novartis International AG (0QLR) Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
22 Mar 2019 6:00 am GNW   Factsheet Novartis International AG (0QLR) Novartis plans for Alcon spin-off on April 9, 2019
18 Mar 2019 6:15 am GNW   Factsheet Novartis International AG (0QLR) Alcon Announces Acquisition of PowerVision, Inc.
14 Mar 2019 4:30 pm GNW   Factsheet Novartis International AG (0QLR) Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
  6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis announces change in Sandoz leadership
10 Mar 2019 11:36 pm GNW   Factsheet Novartis International AG (0QLR) Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW
05 Mar 2019 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®*
04 Mar 2019 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China
28 Feb 2019 12:50 pm GNW   Factsheet Novartis International AG (0QLR) Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
25 Feb 2019 10:55 pm GNW   Factsheet Novartis International AG (0QLR) Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
  6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a)
13 Feb 2019 9:23 pm GNW   Factsheet Novartis International AG (0QLR) Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease
30 Jan 2019 6:00 am GNW   Factsheet Novartis International AG (0QLR) Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
08 Jan 2019 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
07 Jan 2019 10:02 pm GNW   Factsheet Novartis International AG (0QLR) Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder
21 Dec 2018 1:53 pm GNW   Factsheet Novartis International AG (0QLR) Novartis successfully completes acquisition of Endocyte
20 Dec 2018 4:00 pm GNW   Factsheet Novartis International AG (0QLR) Novartis announces offer to acquire CellforCure to expand manufacturing capacity for innovative cell and gene therapies
  6:00 am GNW   Factsheet Novartis International AG (0QLR) Novartis announces new CEO of Oncology Business Unit
19 Dec 2018 6:15 am GNW   Factsheet Novartis International AG (0QLR) Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t